Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Verona Pharma Plc ADR’s stock clocked out at $53.93, down -6.87% from its previous closing price of $57.91. In other words, the price has decreased by -$6.87 from its previous closing price. On the day, 1.01 million shares were traded. VRNA stock price reached its highest trading level at $57.48 during the session, while it also had its lowest trading level at $51.7442.
Ratios:
To gain a deeper understanding of VRNA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.48 and its Current Ratio is at 10.63. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.59.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, ROTH MKM on January 10, 2025, initiated with a Buy rating and assigned the stock a target price of $68.
On October 03, 2024, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $50.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’25 when Rickard Kathleen A. sold 79,264 shares for $8.35 per share. The transaction valued at 661,942 led to the insider holds 2,608,976 shares of the business.
KATHLEEN RICKARD bought 9,908 shares of VRNA for $621,232 on Mar 12 ’25. On Dec 05 ’24, another insider, ZACCARDELLI DAVID, who serves as the President and CEO of the company, sold 640,264 shares for $5.01 each. As a result, the insider received 3,205,226 and left with 14,367,552 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRNA now has a Market Capitalization of 7178460672 and an Enterprise Value of 36471947264. For the stock, the TTM Price-to-Sale (P/S) ratio is 108.67 while its Price-to-Book (P/B) ratio in mrq is 22.31. Its current Enterprise Value per Revenue stands at 862.649 whereas that against EBITDA is -243.197.
Stock Price History:
The Beta on a monthly basis for VRNA is 0.26, which has changed by 2.389692 over the last 52 weeks, in comparison to a change of 0.028231144 over the same period for the S&P500. Over the past 52 weeks, VRNA has reached a high of $70.40, while it has fallen to a 52-week low of $11.39. The 50-Day Moving Average of the stock is -13.84%, while the 200-Day Moving Average is calculated to be 33.53%.
Shares Statistics:
It appears that VRNA traded 1.47M shares on average per day over the past three months and 1854580 shares per day over the past ten days. A total of 84.63M shares are outstanding, with a floating share count of 74.21M. Insiders hold about 12.31% of the company’s shares, while institutions hold 69.85% stake in the company. Shares short for VRNA as of 1741910400 were 9848197 with a Short Ratio of 6.19, compared to 1739491200 on 7783712. Therefore, it implies a Short% of Shares Outstanding of 9848197 and a Short% of Float of 12.0799996.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
